← Back to Search

Immunomodulator

CC-220 + Anti-CD20 mAb for Lymphoma

Phase 1
Waitlist Available
Research Sponsored by Celgene
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subjects must be ≥ 18 years of age at the time of signing the informed consent form (ICF).
Subjects must have a histologically confirmed diagnosis of lymphoma according to 2016 World Health Organization (WHO) classification.
Must not have
Subjects with peripheral neuropathy ≥ Grade 2.
Subjects who have had major surgery ≤ 2 weeks prior to starting CC-220.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 5 years
Awards & highlights

Summary

This trial is testing a new drug, CC-220, to see if it can help people with lymphoma who have not responded to other treatments.

Who is the study for?
Adults over 18 with relapsed or refractory lymphoma, who've had at least two prior treatments and have measurable disease. They must be in fairly good health (ECOG status 0-2), understand the risks of the drug potentially causing birth defects, and agree to follow strict pregnancy prevention measures if they can have children.
What is being tested?
The study is testing CC-220's safety and optimal dose alone and combined with anti-CD20 mAbs (rituximab or obinutuzumab) for treating lymphoma that has returned after treatment. It includes an initial phase to find the best dose followed by a second phase to confirm its effectiveness.
What are the potential side effects?
Potential side effects may include reactions related to immune system suppression, nerve damage symptoms like numbness or tingling (peripheral neuropathy), increased risk of blood clots, allergic reactions to similar drugs previously taken, or other significant medical issues.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
My lymphoma diagnosis is confirmed by lab tests, as per WHO standards.
Select...
I am able to care for myself and perform daily activities.
Select...
My lymphoma has returned or didn't respond to treatment.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have moderate to severe nerve damage.
Select...
I have not had major surgery within the last 2 weeks.
Select...
I am HIV positive.
Select...
I had a stem cell transplant less than 3 months ago or have ongoing side effects.
Select...
I have previously been treated with the drug CC-99282.
Select...
My cancer has spread to my brain or is suspected to.
Select...
I have been diagnosed with lymphoblastic lymphoma.
Select...
I have chronic active hepatitis B.
Select...
I am unable or unwilling to follow the required blood clot prevention treatment.
Select...
I have a serious heart condition.
Select...
I do not have any major health issues that would stop me from joining the study.
Select...
I am on long-term immunosuppressive medication or steroids.
Select...
My aggressive lymphoma has returned and needs urgent treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Maximum Tolerated Dose (MTD)
Recommended Phase 2 Dose (RP2D)
Secondary study objectives
Adverse Events (AEs)
Best Overall Response Rate (ORR)
Complete Response Rate (CRR)
+9 more

Side effects data

From 2021 Phase 2 trial • 289 Patients • NCT03161483
17%
Urinary tract infection
14%
Diarrhoea
14%
Vomiting
14%
Upper respiratory tract infection
12%
Pharyngitis
12%
Nasopharyngitis
10%
Bronchitis
10%
Influenza
10%
Oral herpes
7%
Leukopenia
7%
Nausea
7%
Hypertriglyceridaemia
7%
Pyrexia
7%
Headache
7%
Anaemia
5%
Neutropenia
5%
Abdominal pain upper
5%
Back pain
5%
Hypertension
2%
Suture related complication
2%
Cardiac tamponade
2%
Cholangitis
2%
Implant site pain
2%
Septic shock
2%
Traumatic fracture
2%
Acute kidney injury
2%
Sinusitis
2%
Osteoarthritis
2%
Oropharyngeal pain
2%
Pruritus
2%
Pericarditis
2%
Cholelithiasis
2%
Ischaemic stroke
2%
Abnormal uterine bleeding
100%
80%
60%
40%
20%
0%
Study treatment Arm
0.15mg QD
0.45mg QD
Active Treatment Phase 0.30mg Following Placebo
0.30mg QD
Active Treatment Phase 0.45mg Following Placebo
Placebo

Trial Design

7Treatment groups
Experimental Treatment
Group I: Cohort G - CC-220 plus obinutuzumab in participants with follicular lymphoma grade 1-3aExperimental Treatment2 Interventions
Group II: Cohort F - CC-220 and rituximab with follicular lymphoma grade 1-3aExperimental Treatment2 Interventions
Group III: Cohort E - CC-220 and rituximab in participants with aggressive B-cell lymphomaExperimental Treatment2 Interventions
Group IV: Cohort D -CC-220 monotherapy in participants with aggressive B-cell lymphoma and follicular lymphomaExperimental Treatment1 Intervention
Group V: Cohort C - CC-220 and obinutuzumab in R/R FL or MZL subjectsExperimental Treatment2 Interventions
Subjects with R/R FL (Grade 1 to 3a) or MZL who have been allocated to Cohort C will receive CC-220 in combination with obinutuzumab. * Oral CC-220 at dose specified by cohort dose level from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 12 cycles. * Obinutuzumab will be administered at 1000 mg at C1D1, D8, and D15, and on D1 of every 28-day cycle from C2 to C6.
Group VI: Cohort B- CC-220 and rituximab in R/R B-Cell NHL subjectsExperimental Treatment2 Interventions
Subjects with R/R B-cell Non Hodgkin Lymphoma (NHL) who have been allocated to Cohort B will receive CC-220 in combination with rituximab. * Oral CC-220 at dose specified by cohort dose level from Day 1 to 21 of each 28-day cycle up to PD or maximum 24 cycles. * Rituximab will be administered at 375 mg/m2 IV at C1D1 and then on D8, D15, and D22 of C1 and then every 28-day cycle at D1 from C2 to C5, either by SC administration at a dose of 1400 mg or by IV infusion at a dose of 375 mg/m2.
Group VII: Cohort A- Monotherapy in R/R lymphoma subjectsExperimental Treatment1 Intervention
Subjects with Relapsed or Refractory (R/R) lymphoma who have been allocated to Cohort A will receive CC-220 monotherapy (MonoT). Oral CC-220 at dose specified by cohort dose level from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 24 cycles.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rituximab
1999
Completed Phase 4
~2200
Obinutuzumab
2014
Completed Phase 3
~3470
CC-220
2016
Completed Phase 2
~620

Find a Location

Who is running the clinical trial?

CelgeneLead Sponsor
645 Previous Clinical Trials
130,487 Total Patients Enrolled
88 Trials studying Lymphoma
9,809 Patients Enrolled for Lymphoma
Vijaya Kesanakurthy, M.DStudy DirectorCelgene/BMS
Bristol-Myers SquibbStudy DirectorBristol-Myers Squibb
1,559 Previous Clinical Trials
3,383,654 Total Patients Enrolled
55 Trials studying Lymphoma
10,777 Patients Enrolled for Lymphoma

Media Library

CC-220 (Immunomodulator) Clinical Trial Eligibility Overview. Trial Name: NCT04464798 — Phase 1
CC-220 (Immunomodulator) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04464798 — Phase 1
Lymphoma Research Study Groups: Cohort G - CC-220 plus obinutuzumab in participants with follicular lymphoma grade 1-3a, Cohort C - CC-220 and obinutuzumab in R/R FL or MZL subjects, Cohort B- CC-220 and rituximab in R/R B-Cell NHL subjects, Cohort F - CC-220 and rituximab with follicular lymphoma grade 1-3a, Cohort A- Monotherapy in R/R lymphoma subjects, Cohort E - CC-220 and rituximab in participants with aggressive B-cell lymphoma, Cohort D -CC-220 monotherapy in participants with aggressive B-cell lymphoma and follicular lymphoma
Lymphoma Clinical Trial 2023: CC-220 Highlights & Side Effects. Trial Name: NCT04464798 — Phase 1
~13 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top